Glaucoma 360: Drug targets and reduces episcleral venous pressure in glaucoma
February 3rd 2023Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, took the podium at the New Horizons Forum at the Glaucoma 360 conference in San Francisco to discuss the performance of the company’s episcleral venous pressure eyedrop, QLS-111.
Glaucoma 360: A bird's-eye view of innovation
February 3rd 2023Kristen H. Ingenito, MBA, vice president and director of ophthalmics at Market Scope, discusses the volume of ophthalmologists offering interventional glaucoma treatment as well as emerging therapies in her presentation at the Glaucoma 360 New Horizons Forum.
Novel gene therapy shows promise for treating multiple eye diseases
The results are consistent with those observed, and previously published by the same group, showing benefit in age related macular degeneration models and highlights the potential value of ophNdi1 for multiple eye diseases.
ML6710i photodynamic laser for use with VISUDYNE approved by the FDA
Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.
CDC sounds alarm over eye drops linked to dozens of infections, 1 death
In a news release, the CDC is urging that clinicians and patients immediately discontinue the use of EzriCare Artificial Tears until the epidemiological investigation and laboratory analyses are complete.